Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Talaris Therapeutics, Inc. (TALS), a late-clinical stage cell therapy company, will present at the virtual 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talaris Therapeutics, Inc. (TALS), a late-clinical stage cell therapy company, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM ET. CEO Scott Requadt will lead this presentation, which aims to highlight Talaris's innovative therapies for solid organ transplantation and severe immune and blood disorders. A live webcast of the event will be available on Talaris's investor webpage, remaining accessible for 30 days post-event.
Details
News Market Reaction – TALS
The recorded move for TALS in the trading session of this news was -1.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET.
A live webcast of the presentation will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 30 days.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Marin Bergman
Ten Bridge Communications
marin@tenbridgecommunications.com
(818) 516-2746
Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.